The significance of HER-2/neu/c-erbB-2 gene amplification in benign and malignant breast disease

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 28, Issue 3, 1997, Pages 631-640

  Supanaranond, Kasama ^a   Sukarayodhin, Saowakon ^b   Tanyakaset, Manu ^b   Balachandra, Kruavon ^a   Jullaksorn, Duangrat ^a   Rienkijkarn, Mati ^b   Hoisanka, Narin ^a   Tantivanich, Surang ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST DISEASE; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; GENE AMPLIFICATION; GENETICS; HUMAN; INCIDENCE; LYMPH NODE METASTASIS; MENOPAUSE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADULT; AGE DISTRIBUTION; AGED; BREAST DISEASES; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; INCIDENCE; LYMPHATIC METASTASIS; MENOPAUSE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROGNOSIS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 0031219588     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Ali IU, Campbell G, Lidereau R, Callahan R. Amplification of c-erbB-2 and aggressive human breast tumors. Science 1988a; 240 : 1795-6.
2. Ali IU, Campbell G, Lidereau R, Callahan R. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast carcinoma. Oncogene Res 1988b; 3 : 139-46.
3. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10 : 599-605.
4. Berns EMJJ, Foekens JA, van Putten WL, et al. Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/neu amplification. J Steroid Biochem Mol Biol 1992; 43 : 13-9.
5. Berns EMJJ, Foekens JA, van Staveren IL, et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995; 159 : 11-8.
6. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990; 50 : 4332-7.
7. Borresen AL, Ottestad L, Gaustad A, et al. Amplification and protein over-expression of the neu/HER-2/c-erbB-2 proto-oncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis. Br J Cancer 1990; 62 : 585-90.
8. Chen Y, Dong J, Lu Y, McGee JO. Quantitative detection of amplification of proto-oncogenes in breast cancer. Chin Med J 1995; 108 : 849-54.
9. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991; 51 : 944-8.
10. Cline MJ, Battifora H, Yokota J. Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease. J Clin Oncol 1987; 5 : 999-1006.
11. Coussens L, Yang-Feng TL, Liao Y-C, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230 : 1132-9.
12. Descotes F, Pavy JJ, Adessi GL. Human breast cancer: correlation study between HER-2/neu amplification and prognostic factors in an unselected population. Anticancer Res 1993; 13 : 119-24.
13. Frye RA, Benz CC, Liu E. Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 1989; 4 : 1153-7.
14. Fukushige S, Matsubara K, Yoshida M, et al. Localization of a novel v-erbB-related gene c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol 1986; 6: 955-8.
15. Gray PW, Goeddel DV. Structure of the human immune interferon gene. Nature 1982; 298 : 859-63.
16. Gusterson BA, Machin LG, Gullick WJ, et al. c-erbB-2 expression in benign and malignant breast disease. Br J Cancer 1988; 58 : 453-7.
17. Imyanitov EN, Chernitsa OI, Serova OM, Nikoforova IF, Pluzhnikova GF, Knyazev PG. Amplification of HER-2 (erbB-2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients. Neoplasma 1993; 40 : 35-9.
18. Kerns BJ, Jordan PA, Huper G, Marks JR, Iglehart JD, Layfied LJ. Assessment of c-erbB-2 amplification by immunohistochemistry in paraffin-embedded breast cancer. Mod Pathol 1993; 6 : 673-8.
19. Knyazev PG, Imyanitov EN, Chernitsa OI, Nikiforova IF. Loss of heterozygosity at chromosome 17p is associated with HER-2 amplification and lack of nodal involvement in breast cancer. Int J Cancer 1993; 53 : 11-6.
20. Kraus MH, Popescu NC, Amsbaugh SC, King CR. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 1987; 6 : 605-10.
21. Liu E, Thor A, He M, Barcos M, Ljung BM, Benz C. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 1992; 7 : 1027-32.
22. Lizard-Nacol S, Lidereau R, Collin F, et al. Benign breast disease: absence of genetic alterations at several loci implicated in breast cancer malignancy. Cancer Res 1995; 55 : 4416-9.
23. Millikan R, Hulka B, Thor A, et al. p53 mutations in benign breast tissue. J Clin Oncol 1995; 13 : 2293-300.
24. Neubauer A, Neubauer B, He M, et al. Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene 1992; 7 : 1019-25.
25. Ohno S, Taniguchi T. Inducer-responsive expression of the cloned human interferon beta 1 gene introduced into cultured mouse cells. Nucleic Acids Res 1982; 10 : 967-77.
26. Paik S, Hazan R, Fisher ER, et al. Pathological findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein over-expression in primary breast cancer. J Clin Oncol 1990; 8 : 103-12.
27. Paterson MC, Dietrich KD, Danyluk J, et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991; 51: 556-67.
28. Regidor PA, Callies R, Schindler AE. Level of c-erbB-2 oncoprotein in the homogenate of malignant and benign breast tumor samples. Eur J Gynaecol Oncol 1995; 16 : 130-7.
29. Rilke F, Colnaghi MI, Cascinelli N, et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991; 49 : 44-9.
30. Riviere A, Becker J, Loning T. Comparative investigation of c-erbB-2/neu expression in head and neck tumor and mammary cancer. Cancer 1991; 67 : 2142-9.
31. r tumor antigen. Nature 1984; 312 : 513-6.
32. Scorilas A, Yotis J, Stravolemos K, et al. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Anticancer Res 1995; 15 : 1543-7.
33. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993; 11 : 1936-42.
34. Seshadri R, Matthews C, Dobrovic A, Horsfall DJ. The significance of oncogene amplification in primary breast cancer. Int J Cancer 1989; 43 : 270-2.
35. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235 : 177-82.
36. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244 : 707-12.
37. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7 : 1120-8.
38. Taparowsky E, Shimizu K, Goldfarb M, WiglerM. Structure and activation of the human N-ras gene. Cell 1983; 34 . 581-6.
39. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73 : 2359-65.
40. Tiwari RK, Borgen PI, Wong GY, Cordon-Cardo C, Osborne MP. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 1992; 12 : 419-25.
41. Tommasi S, Giannella C, Paradiso A, et al. HER-2/neu gene in primary and local metastatic axillary lymph nodes in human breast tumors. Int J Biol Markers 1992; 7 : 107-13.
42. Tsuda H, Hirohashi S, Shimosato Y, et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene coamplification units:hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 1989; 49 : 3104-8.
43. Tsutsumi Y, Naber SP, DeLellis RA, et al. Neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues. Hum Pathol 1990; 21 : 750-8.
44. Valeron PF, Chirino R, Fernandez L, et al. Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer. Int J Cancer 1996, 65 : 129-33
45. van de Vijer MJ, Mooi WJ, Peterse JL, Nusse R. Amplification and overexpression of the neu oncogene in human breast carcinomas. Eur J Surg Oncol 1988; 14 : 111-4.
46. Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA. Alterations to either c-erbB-2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1987; 1 : 423-30.
47. Venter DJ, Tuzi NL, Kumar S, Gullick WJ. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet 1987; 2 : 69-72.
48. Walker RA, Gullick WJ, Varley JM. An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer 1989; 60 : 426-9.
49. Wright C, Angus B, Nicholson S, et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989; 49 : 2087-90.
50. Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor. Nature 1986; 319 : 230-4.
51. Zeillinger R, Kury F, Czerwenka K, et al. HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. Oncogene 1989; 4 : 109-14.
52. Zhou D-J, Ahuja H, Cline MJ. Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene 1989; 4 : 105-8.